• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病发展的分子基础。

Molecular basis of the development of Parkinson's disease.

作者信息

Absalyamova Margarita, Traktirov Dmitrii, Burdinskaya Viktoria, Artemova Valeria, Muruzheva Zamira, Karpenko Marina

机构信息

Peter the Great St Petersburg Polytechnic University, Russia.

FSBSI Institute of Experimental Medicine, Russia.

出版信息

Neuroscience. 2025 Jan 26;565:292-300. doi: 10.1016/j.neuroscience.2024.12.009. Epub 2024 Dec 7.

DOI:10.1016/j.neuroscience.2024.12.009
PMID:39653246
Abstract

Parkinson's disease is one of the most prevalent neurodegenerative motor disorders worldwide with postural instability, bradykinesia, resting tremor and rigidity being the most common symptoms of the disease. Despite the fact that the molecular mechanisms of Parkinson's disease pathogenesis have already been well described, there is still no coherent picture of the etiopathogenesis of this disease. According to modern concepts, neurodegeneration is induced mainly by oxidative stress, neuroinflammation, dysregulation of cerebral proteostasis, apoptotic dysregulation, and impaired autophagy. This review describes how various factors contribute to neurodegeneration in Parkinson's disease. Understanding the factors affecting fundamental cellular processes and responsible for disease progression may help develop therapeutic strategies to improve the quality of life of patients suffering from the disease. The review also discusses the role of calpains in the development of Parkinson's disease. It is known that α-synuclein is a substrate of calcium-dependent proteases of the calpain family. Truncated forms of α-synuclein are not only involved in the process of formation of the aggregates, but also increase their toxicity.

摘要

帕金森病是全球最常见的神经退行性运动障碍之一,姿势不稳、运动迟缓、静止性震颤和肌强直是该病最常见的症状。尽管帕金森病发病机制的分子机制已得到充分描述,但对于该疾病的病因发病机制仍缺乏连贯的认识。根据现代概念,神经退行性变主要由氧化应激、神经炎症、脑内蛋白质稳态失调、凋亡失调和自噬受损引起。本综述描述了各种因素如何导致帕金森病中的神经退行性变。了解影响基本细胞过程并导致疾病进展的因素可能有助于制定治疗策略,以改善患有该疾病患者的生活质量。该综述还讨论了钙蛋白酶在帕金森病发展中的作用。已知α-突触核蛋白是钙蛋白酶家族中钙依赖性蛋白酶的底物。α-突触核蛋白的截短形式不仅参与聚集体的形成过程,还会增加其毒性。

相似文献

1
Molecular basis of the development of Parkinson's disease.帕金森病发展的分子基础。
Neuroscience. 2025 Jan 26;565:292-300. doi: 10.1016/j.neuroscience.2024.12.009. Epub 2024 Dec 7.
2
Calpain in the cleavage of alpha-synuclein and the pathogenesis of Parkinson's disease.钙蛋白酶在α-突触核蛋白裂解中的作用及其在帕金森病发病机制中的作用。
Prog Mol Biol Transl Sci. 2019;167:107-124. doi: 10.1016/bs.pmbts.2019.06.007. Epub 2019 Aug 19.
3
Parkinson's disease risk genes act in glia to control neuronal α-synuclein toxicity.帕金森病风险基因在神经胶质细胞中发挥作用,以控制神经元α-突触核蛋白毒性。
Neurobiol Dis. 2021 Nov;159:105482. doi: 10.1016/j.nbd.2021.105482. Epub 2021 Aug 11.
4
The central theme of Parkinson's disease: α-synuclein.帕金森病的核心主题:α-突触核蛋白。
Mol Neurobiol. 2013 Apr;47(2):460-5. doi: 10.1007/s12035-012-8369-3. Epub 2012 Nov 23.
5
Translational molecular imaging and drug development in Parkinson's disease.帕金森病的转化分子影像学与药物研发。
Mol Neurodegener. 2023 Feb 10;18(1):11. doi: 10.1186/s13024-023-00600-z.
6
Neuron-Astrocyte Interactions in Parkinson's Disease.神经元-星形胶质细胞在帕金森病中的相互作用。
Cells. 2020 Dec 7;9(12):2623. doi: 10.3390/cells9122623.
7
The Nigral Coup in Parkinson's Disease by α-Synuclein and Its Associated Rebels.帕金森病中α-突触核蛋白及其相关“叛乱者”引发的黑质打击。
Cells. 2021 Mar 9;10(3):598. doi: 10.3390/cells10030598.
8
α-Synuclein and Lewy pathology in Parkinson's disease.帕金森病中的α-突触核蛋白与路易小体病理改变
Curr Opin Neurol. 2015 Aug;28(4):375-81. doi: 10.1097/WCO.0000000000000215.
9
Calpain activation and progression of inflammatory cycles in Parkinson's disease.钙蛋白酶激活与帕金森病炎症周期进展。
Front Biosci (Landmark Ed). 2022 Jan 13;27(1):20. doi: 10.31083/j.fbl2701020.
10
Targeting alpha-synuclein for the treatment of Parkinson's disease.针对帕金森病的α-突触核蛋白靶向治疗。
CNS Neurol Disord Drug Targets. 2012 Mar;11(2):174-9. doi: 10.2174/187152712800269678.

引用本文的文献

1
Early synaptic changes and reduced brain connectivity in PD-like mice with depressive phenotype.具有抑郁表型的帕金森病样小鼠的早期突触变化及脑连接性降低
NPJ Parkinsons Dis. 2025 Aug 13;11(1):242. doi: 10.1038/s41531-025-01073-1.
2
α-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges.突触核蛋白病中的α-突触核蛋白病理学:机制、生物标志物及治疗挑战
Int J Mol Sci. 2025 Jun 4;26(11):5405. doi: 10.3390/ijms26115405.
3
Protective Effect of the LRRK2 Kinase Inhibition in Human Fibroblasts Bearing the Genetic Variant GBA1 K198E: Implications for Parkinson's Disease.
LRRK2激酶抑制对携带遗传变异GBA1 K198E的人成纤维细胞的保护作用:对帕金森病的意义。
Neuromolecular Med. 2025 May 21;27(1):42. doi: 10.1007/s12017-025-08864-y.